Acrivon Therapeutics, Inc. Common Stock (ACRV)

USD 6.69

(-7.21%)

Market Cap (In USD)

208.3 Million

Revenue (In USD)

-

Net Income (In USD)

-60.38 Million

Avg. Volume

100.13 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.19-11.9
PE
-
EPS
-
Beta Value
1.7012562
ISIN
US0048901096
CUSIP
004890109
CIK
1781174
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Peter Blume-Jensen M.D., Ph.D.
Employee Count
-
Website
https://www.acrivon.com
Ipo Date
2022-11-15
Details
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.